Maulik Nanavaty Sells 3,038 Shares of Boston Scientific Co. (BSX) Stock

Boston Scientific Co. (NYSE:BSX) SVP Maulik Nanavaty sold 3,038 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $36.74, for a total value of $111,616.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Maulik Nanavaty also recently made the following trade(s):

  • On Monday, April 15th, Maulik Nanavaty sold 3,039 shares of Boston Scientific stock. The stock was sold at an average price of $37.81, for a total value of $114,904.59.
  • On Friday, March 15th, Maulik Nanavaty sold 3,038 shares of Boston Scientific stock. The stock was sold at an average price of $40.11, for a total value of $121,854.18.
  • On Friday, February 15th, Maulik Nanavaty sold 3,039 shares of Boston Scientific stock. The stock was sold at an average price of $40.32, for a total value of $122,532.48.

BSX stock opened at $37.32 on Friday. Boston Scientific Co. has a twelve month low of $29.96 and a twelve month high of $41.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.39 and a quick ratio of 1.12. The company has a market cap of $51.90 billion, a P/E ratio of 25.39, a P/E/G ratio of 2.21 and a beta of 0.83.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.36 by ($0.01). Boston Scientific had a net margin of 18.08% and a return on equity of 24.65%. The company had revenue of $2.49 billion for the quarter, compared to the consensus estimate of $2.54 billion. During the same period last year, the business earned $0.33 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Equities research analysts forecast that Boston Scientific Co. will post 1.55 earnings per share for the current fiscal year.

A number of research analysts have recently commented on BSX shares. Evercore ISI upgraded Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 target price for the company in a research note on Monday, May 13th. Needham & Company LLC restated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a research note on Monday, May 13th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, April 25th. Canaccord Genuity lowered their target price on Boston Scientific from $45.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. Finally, Argus raised their target price on Boston Scientific from $43.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 13th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $41.53.

Several institutional investors have recently bought and sold shares of BSX. Vanguard Group Inc increased its holdings in shares of Boston Scientific by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 101,453,358 shares of the medical equipment provider’s stock worth $3,905,954,000 after purchasing an additional 1,367,053 shares in the last quarter. DNB Asset Management AS increased its holdings in shares of Boston Scientific by 112.4% in the 4th quarter. DNB Asset Management AS now owns 364,282 shares of the medical equipment provider’s stock worth $12,874,000 after purchasing an additional 192,752 shares in the last quarter. Ipswich Investment Management Co. Inc. bought a new stake in shares of Boston Scientific in the 4th quarter worth $28,000. Oakbrook Investments LLC increased its holdings in shares of Boston Scientific by 17.8% in the 4th quarter. Oakbrook Investments LLC now owns 93,525 shares of the medical equipment provider’s stock worth $3,305,000 after purchasing an additional 14,100 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of Boston Scientific by 4.8% in the 4th quarter. Quadrant Capital Group LLC now owns 6,532 shares of the medical equipment provider’s stock worth $215,000 after purchasing an additional 302 shares in the last quarter. 91.43% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Maulik Nanavaty Sells 3,038 Shares of Boston Scientific Co. (BSX) Stock” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/19/maulik-nanavaty-sells-3038-shares-of-boston-scientific-co-bsx-stock.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Are sell-side analysts objective?

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.